Longitudinal analysis of antibody decay in convalescent COVID-19 patients
Open Access
- 18 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-9
- https://doi.org/10.1038/s41598-021-96171-4
Abstract
Determining the sustainability of antibodies targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for predicting immune response against the Coronavirus disease 2019 (COVID-19). To quantify the antibody decay rates among the varying levels of anti-nucleocapsid (anti-N) Immunoglobulin G (IgG) in convalescent COVID-19 patients and estimate the length of time they maintained SARS-CoV-2 specific antibodies, we have collected longitudinal blood samples from 943 patients over the course of seven months after their initial detection of SARS-CoV-2 virus by RT-PCR. Anti-N IgG levels were then quantified in these blood samples. The primary study outcome was the comparison of antibody decay rates from convalescent patients with high or low initial levels of antibodies using a mixed linear model. Additional measures include the length of time that patients maintain sustainable levels of anti-N IgG. Antibody quantification of blood samples donated by the same subject multiple times shows a gradual decrease of IgG levels to the cutoff index level of 1.4 signal/cut-off (S/C) on the Abbott Architect SARS-CoV-2 IgG test. In addition, this study shows that antibody reduction rate is dependent on initial IgG levels, and patients with initial IgG levels above 3 S/C show a significant 1.68-fold faster reduction rate compared to those with initial IgG levels below 3 S/C. For a majority of the donors naturally occurring anti-N antibodies were detected above the threshold for only four months after infection with SARS-CoV-2. This study is clinically important for the prediction of immune response capacity in COVID-19 patients.Funding Information
- U.S. Department of Veterans Affairs (COVID19-8900-06)
- National Institutes of Health (RF1AG063913)
This publication has 36 references indexed in Scilit:
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, IdahoJournal of Clinical Microbiology, 2020
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesCell, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B CellsCell, 2020
- Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent IndividualsPublished by Cold Spring Harbor Laboratory ,2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal studyClinica Chimica Acta; International Journal of Clinical Chemistry, 2020
- Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kineticscclm, 2020